Immupharma Share Discussion Threads

[aimingupward2] 07/4/2018 11:13

h2owater, do you know (or does anyone know?), whether Simbec-Orion agreed to take a significant proportion of their fees as IMM shares irrespective of the trial results, or only if sufficiently positive?

[obiterdicta] 07/4/2018 11:06

Scsw says £5 plus on positive results, deal at multiples of that within weeks. Broker apptd.

OD

[andyr42] 07/4/2018 11:01

chadders, thanks. Is there anything else mentioned about IMM in SCSW? I know its not fair to post the full article but can you paraphrase it please?

[wildbunch] 07/4/2018 10:16

Chadders. Thanks. Something well worth posting. What bulletin boards are for!

[chadders] 07/4/2018 09:39

Note in SCSW this morning. Met with company. Reckon top line results the week after database lock on April 6th.

[easymonez] 07/4/2018 09:31

Wont be results next week but a big pharma could make a move with big money for a first option. Imm are only saying they will go it alone to force a hand. Theyre ultimately powerless as an offer can be made and accepted by shareholders. They can however put a legally binding option in place to partner with a company, which could then in itself help prevent a hostile takeover.

[h2owater] 07/4/2018 09:31

Back in 2015 Simbec-Orion bought 206% premium shares! Confidence!


----------------------------------------------------------------------




ImmuPharma Shares Up 22% On Simbec-Orion Lupuzor Agreement LONDON (Alliance News) - Shares in ImmuPharma PLC are trading up 22% Thursday morning after it ...
Alliance News22 January, 2015 | 8:32AM Email Form
LONDON (Alliance News) - Shares in ImmuPharma PLC are trading up 22% Thursday morning after it said it has entered an agreement with Simbec-Orion Group Ltd to begin a phase III study of ImmuPharma's Lupuzor treatment for lupus and will get an investment from the company.

Simbec-Orion has agreed it will reinvest a significant proportion of its fees into new ImmuPharma shares at a price of 150 pence per share, a 206% premium on the company's closing mid-market price Wednesday. Shares in ImmuPharma are trading up 22% at 60.00 pence Thursday morning.

It is expected that Simbec-Orion will subscribe for around 900,000 new shares over the duration of the study.

ImmuPharma said that the deal is attractive because it allows it to retain the rights to Lupuzor until commercialisation.

"This opens many options for the company for further corporate deals including following in the path of all "big biotechs" by generating our own sales," said Chief Executive Officer Dimitri Dimitriou in a statement.

Lupuzo has been granted fast-track status by the US Food and Drug Administration. The company said a multi-centre study will commence immediately, and will recruit patients across Europe, the US and other regions.

[lucicavi] 07/4/2018 09:29

There once was a man called hamhamham from China,
Who wasn't a very good climber,
He slipped on a rock, slit his c*ck,
And now he has a virgina!

[easymonez] 07/4/2018 09:25

can't be too many placing shares left to churn. When they're flipped this will go north like a coiled spring and 200p will be smashed. Pre results I suspect, maybe Monday or Tuesday with this volume.

[lucicavi] 07/4/2018 09:25

smells like bad meat, hamhamham gone orf

[easymonez] 07/4/2018 09:23

I smell subtle deramping gangs on this board, and they smell like rotten eggs

[hamhamham1] 07/4/2018 09:20

Bench. Really shows the true quality of IMM shareholders. It's a real advert for investing here!

[benchmark] 07/4/2018 09:16

hamhamham - you wouldnt want them on a dinner-party or wedding invitation list for sure! A little slip and the real character traits show through

[pretax2] 07/4/2018 09:15

I think the site has now said everything relevant to the upcoming RNS. There’ll be the usual panic mongers infusing the B.B. on any dips, but the board and share price are ready for results now.
Bring it on.

[qazwsxedc69] 07/4/2018 09:14

Re the earlier comment, Sicilian Kan didn't sell out at 90p. But he did re-risk around 80p, and had a free ride from there. I personally thought it was a little early, but then like me he was in from the 20s and 30s so you can't begrudge him. I'm 'sure' he is still around and still long, but one can't blame him for not coming anywhere near this toxic thread.

[hamhamham1] 07/4/2018 09:00

L0mg. Didn't have you down as the gutter type as well? Shows u can be wrong about people.

[njb67] 07/4/2018 08:29

ash

A company can not RNS an "informal" sharing of information between CRO and themselves. They need results confirmed in writing.

Btw, the report will contain more than the primary outcomes. Will need info on patient demographics (to demo both groups are sufficiently similar so that results are robust), safety data (to confirm no difference between the group), info on conduct of study etc.

Not long to wait now....

[andyr42] 07/4/2018 08:23

SK brought me to this thread too. I vaguely remember he sold out last year when the price was around 90p. I wonder if he is still around? Undoubtedly the quality of this board has deteriorated over time.

[hamila01] 07/4/2018 03:49

Chadders - I am eternally grateful that Sicilian Kan did create this thread. His/her research helped me so much in understanding the IMM proposition.Many of us LTH's owe S_K a big drink or two....And yes, totally agree. Sad how the quality of forum and posters has declined so markedly over the last few months.

[harbourside] 06/4/2018 23:47

Long, usually follow your posts with interest, not sure what we are missing, little bit too cryptic for me, be good if you could enlighten, thanks.